Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The impact of BCL7A loss on myeloma cell growth and future therapeutic strategies

Chandraditya Chakraborty • 26 Aug 2022
IMS 2022
Multiple Myeloma

Chandraditya Chakraborty, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the impact of BCL7A loss on myeloma cell growth, and further explains how better understanding the interaction between BCL7A and other genes may allow therapeutic targets to be developed. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals